Phase 3 N=355 Randomized Double-blind Treatment

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

Molluscum Contagiosum

Bottom Line

View on ClinicalTrials.gov: NCT03927703 ↗

Enrolled (actual)

355

Serious AEs

0.6%

Results posted

Jan 2023

Primary outcome: Primary: Complete Clearance of All Treatable MC at Week 12 — 71; 24 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: SB206 12% (Drug); Placebo (Drug)
Age: Pediatric, Adult, Older Adult · 0+ yrs
Sex: All
Sponsor: Novan, Inc.
Primary completion: Nov 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Complete Clearance of All Treatable MC at Week 12	71; 24	—
SECONDARY Complete Clearance of All Treatable MC at Week 8	33; 7	—

Summary

This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.

Eligibility Criteria

Inclusion Criteria

Be 6 months of age or older, and in good general health;
Have a written informed consent form signed by subject or a parent or legal guardian and an assent form as required;
Have between 3 and 70 treatable MC at Baseline;
Female subjects age 9 and above must have a negative UPT at Baseline;
Female subjects age 9 and above must agree to practice a medically acceptable form of birth control during the study and for 30 days after Week 12/ET1;
Be willing and able to follow study instructions and likely to complete all study requirements.

Exclusion Criteria

Have strongly suggested sexually transmitted MC and do not agree to refrain from sexual activities throughout the study period.
Are immunosuppressed, have immunodeficiency disorder, or are on immunosuppressive treatment;
Have significant injury on and/or surrounding MC that may impact ability to treat and count lesions;
Have received treatment with topical calcineurin inhibitors or steroids on MC or within 2 cm of MC lesions within 14 days prior to Baseline;
Have received treatment for MC during the 14 days prior to Baseline with podophyllotoxin, imiquimod, cantharidin, sinecatechins, topical retinoids, oral or topical zinc, or other homeopathic or over the counter (OTC) products including, but not limited to, ZymaDerm and tea tree oil, cimetidine and other histamine H2 receptor antagonists (including Zantac);
Have received surgical procedures related to MC (cryotherapy, curettage, other) within 14 days prior to Baseline;
Have MC only in periocular area;
Female subjects who are pregnant, planning a pregnancy or breastfeeding;
Have known hypersensitivity to any ingredients of SB206 or Vehicle Gel including excipients;
Have participated in a previous study with a berdazimer sodium product (SB204, SB206, SB208, SB414);
Have more than 1 family member currently participating in a study with a berdazimer sodium product (SB204, SB206, SB208, SB414).
Have participated in any other trial of an interventional investigational drug or device within 14 days or concurrent participation in another interventional research study.
History or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03927703). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.